Latest Current Report
Filed: 2026-04-23
Key Insights
- VolitionRx received notice of non-compliance with NYSE American listing standards across three separate equity thresholds ($2M, $4M, and $6M requirements), indicating significant financial distress and accumulated losses over multiple fiscal years.
- The company has been granted until August 6, 2027 to regain compliance with listing standards, during which it remains listed but subject to periodic NYSE American review; failure to demonstrate sufficient progress or achieve compliance could trigger delisting proceedings.
- The company's equity position has deteriorated to the point where it is ineligible for any exemptions (including the $50M market cap exemption), suggesting market capitalization has declined substantially and financial metrics are severely compromised.
- The acceptance of the remediation plan provides a 16-month runway, but the company faces significant execution risk in restructuring operations and finances while competing in the healthcare diagnostics market with limited apparent resources.